Search

CN-121971659-A - AIE diagnosis and treatment agent and preparation method and application thereof

CN121971659ACN 121971659 ACN121971659 ACN 121971659ACN-121971659-A

Abstract

The invention provides an AIE diagnosis and treatment agent and a preparation method and application thereof, wherein the AIE diagnosis and treatment agent is prepared by mixing bovine serum albumin solution and AIE molecular solution, performing ultrasound, adding medicine molecular solution, stirring and dripping copper ion solution to obtain a material ARC@BSA, and the AIE diagnosis and treatment agent comprises a carrier, wherein the carrier is bovine serum albumin, and is loaded with AIE molecules, medicine molecules and copper ions, and the AIE diagnosis and treatment agent is applied to fluorescent quantitative detection, cell imaging and differentiation, living body layer tumor positioning tracing or photodynamic therapeutic equipment of glutathione. The technical scheme of the invention can improve the in vivo availability of AIE molecules and promote the development of diversified application of AIE materials.

Inventors

  • CHEN HANGRONG
  • MIAO RUNJIE

Assignees

  • 中国科学院上海硅酸盐研究所

Dates

Publication Date
20260505
Application Date
20260209

Claims (10)

  1. 1. The AIE diagnosis and treatment agent is characterized by comprising a carrier, wherein the carrier is bovine serum albumin, and AIE molecules, drug molecules and copper ions are loaded on the carrier.
  2. 2. The AIE diagnostic reagent according to claim 1, wherein the AIE molecule has the structural formula: 。
  3. 3. The AIE as claimed in claim 1, wherein the drug molecule is resveratrol.
  4. 4. The AIE diagnosis and treatment agent according to claim 1, wherein the copper ions are introduced onto the carrier by using CuCl 2 ·2H 2 O solution as a raw material.
  5. 5. The AIE preparation according to claim 1, wherein the mass ratio of the carrier to the AIE molecule is 95-105:1.
  6. 6. The AIE diagnosis and treatment agent according to claim 1, wherein the mass ratio of the carrier to the drug molecules is 5-8:1.
  7. 7. The method for preparing AIE diagnosis and treatment agent according to claim 1, comprising: step 1, mixing bovine serum albumin solution and AIE molecular solution, and carrying out ultrasonic treatment; step 2, adding a drug molecule solution, and stirring at room temperature; Step 3, adding glutaraldehyde solution, continuously stirring, and removing the solvent after the reaction is finished to obtain a material AR@BSA; And step 4, dropwise adding the copper ion solution into the AR@BSA solution, and reacting to obtain the material ARC@BSA.
  8. 8. The method according to claim 7, wherein the step 1 comprises preparing an aqueous solution of bovine serum albumin, and dropping an aqueous solution of AIE molecules in tetrahydrofuran while performing ultrasound.
  9. 9. The method of preparing AIE diagnosis and treatment agent according to claim 7, wherein the material AR@BSA is obtained by purifying, washing, centrifuging and collecting the solvent removed by rotary evaporation after the reaction in step 3.
  10. 10. Use of an AIE diagnostic and therapeutic agent according to any one of claims 1 to 6 in fluorescent quantitative detection, cellular imaging and differentiation of glutathione, in vivo tumor location tracking or photodynamic therapy devices.

Description

AIE diagnosis and treatment agent and preparation method and application thereof Technical Field The invention relates to the technical field of fluorescent materials, in particular to an AIE diagnosis and treatment agent and a preparation method and application thereof. Background Currently, efficient diagnosis and treatment of severe diseases such as tumors still need to rely on traditional modes of "diagnosis" and "treatment" separation. Although traditional imaging techniques can provide lesion information, it is often not possible to perform treatment simultaneously. Therefore, a nano delivery system with disease marker responsiveness is designed, so that the space-time information of disease treatment is obtained, and the nano delivery system has extremely high value and important potential for improving the disease treatment effect. In the construction of the diagnosis and treatment nano platform, fluorescent molecules are favored by researchers due to the characteristics of simple operation, high sensitivity, low cost and the like, and part of fluorescent molecules have the property of photosensitizers and can generate toxic Reactive Oxygen Species (ROS) under the excitation of light, so that the fluorescent molecules are widely applied to disease diagnosis and treatment. However, in the high concentration or aggregation state of the traditional fluorescent material, aggregation fluorescence quenching (ACQ) phenomenon exists due to pi-pi accumulation among molecules, so that the detection performance and the disease diagnosis and treatment effect are obviously affected. The emerging aggregation-induced emission (AIE) molecules overcome the limitations of traditional fluorescent molecules, and the fluorescence in an aggregated state is rapidly enhanced, so that the light-emitting efficiency is high, the light stability is good, and the background noise is low. In addition, AIE molecules can efficiently generate ROS in an aggregation state, energy is not dissipated through a non-radiative channel, energy transfer from a lowest excited singlet state (S1) to a lowest triplet state (T1) is promoted, ROS generation efficiency is improved, and Photodynamic (PDT) treatment effect is remarkably enhanced. Therefore, the AIE molecule has obvious advantages in the fields of construction of tumor imaging and diagnosis and treatment integrated platforms and the like. However, the AIE molecules are not sufficiently water-soluble and aggregation-controllable in complex physiological environments. And the AIE molecules and the biocompatible carrier are effectively integrated, so that the in vivo availability of the AIE molecules can be improved, and the development of diversified application of AIE materials can be promoted. Disclosure of Invention Aiming at the problems in the prior art, the invention aims to provide a novel AIE diagnosis and treatment agent and a preparation method and application thereof. In one aspect, the invention provides an AIE diagnosis and treatment agent, which comprises a carrier, wherein the carrier is bovine serum albumin, and AIE molecules, drug molecules and copper ions are loaded on the carrier. Preferably, the AIE molecule has the structural formula: 。 Preferably, the drug molecule is resveratrol. Preferably, the copper ions are introduced onto the carrier by taking CuCl 2·2H2 O solution as a raw material. Preferably, the mass ratio of the carrier to the AIE molecules is 95-105:1. Preferably, the mass ratio of the carrier to the drug molecules is 5-8:1. In another aspect, the present invention provides a method for preparing the AIE diagnosis and treatment agent, including: step 1, mixing bovine serum albumin solution and AIE molecular solution, and carrying out ultrasonic treatment; step 2, adding a drug molecule solution, and stirring at room temperature; Step 3, adding glutaraldehyde solution, continuously stirring, and removing the solvent after the reaction is finished to obtain a material AR@BSA; And step 4, dropwise adding the copper ion solution into the AR@BSA solution, and reacting to obtain the material ARC@BSA. Preferably, the step 1 comprises preparing an aqueous solution of bovine serum albumin, and dripping a tetrahydrofuran solution of AIE molecules while ultrasonic treatment. Preferably, the material AR@BSA is obtained by purifying, washing and centrifuging after the solvent is removed by rotary evaporation after the reaction in the step 3 is finished. On the other hand, the invention provides the application of the AIE diagnosis and treatment agent in glutathione, cell imaging, differentiation, tumor positioning tracing of living body layers or fluorescent quantitative detection of photodynamic therapeutic equipment. The technical scheme of the invention has the following advantages: 1. The technical scheme of the invention provides a novel fluorescent diagnosis and treatment agent based on aggregation-induced emission molecules, which can realize in-vitro fluores